Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha
Cognition”, or the “Company”), a biopharmaceutical company
committed to developing novel therapies for debilitating
neurodegenerative disorders, today announced the pricing of its
upsized public offering of 8,695,653 common shares at a public
offering price of $5.75 per share, for gross proceeds of
approximately $50 million, before deducting underwriting discounts,
commissions, and estimated offering expenses. In addition, the
Company has granted the underwriters a 30-day option to purchase up
to an additional 1,184,592 common shares to cover over-allotments
at the public offering price, less the underwriting discount. All
of the common shares are being offered by the Company. The offering
is expected to close on November 13, 2024, subject to the
satisfaction of customary closing conditions.
The Company has received approval to list its common shares on
the Nasdaq Capital Market under the symbol “ACOG” and is expected
to begin trading on Nasdaq today, November 12, 2024.
The Company intends to use the proceeds towards the
commercialization and launch of ZUNVEYLTM in Alzheimer’s Disease,
further research and development of its pipeline product
candidates, continued commercial CMC activities (chemistry,
manufacturing, and controls), and for working capital and general
corporate purposes.
“This offering serves as a tremendous milestone for Alpha
Cognition, as we begin the commercialization of our FDA-approved
drug, ZUNVEYL, for the treatment of mild-to-moderate Alzheimer’s
Disease,” said Michael McFadden, Chief Executive Officer and
Director of the Company. "This financing puts our balance sheet in
a position of meaningful strength and provides the necessary
foundation for a successful commercial launch, with ample runway to
scale over the next few years. We are thrilled to welcome a number
of new, high-quality investors to our Nasdaq listing, who also see
the benefits of ZUNVEYL and the exciting opportunity for our
platform.”
Titan Partners Group, a division of American Capital Partners,
is acting as Sole Bookrunner for the offering.
The securities were sold pursuant to a registration statement on
Form S-1 (File No. 333-280196) relating to these securities and a
related registration statement on Form S-1 MEF that became
effective upon its filing in accordance with Rule 462(b) under the
Securities Act of 1933, as amended. The Offering is being made only
by means of a prospectus. A copy of the final prospectus related to
the Offering may be obtained, when available, from Titan Partners
Group LLC, a division of American Capital Partners, LLC, 4 World
Trade Center, 29th Floor, New York, NY 10007, or via email at
prospectus@titanpartnersgrp.com or telephone at (929) 833-1246. In
addition, a copy of the final prospectus, when available, relating
to the Offering may be obtained via the SEC's website at
www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical
company dedicated to developing treatments for patients suffering
from neurodegenerative diseases, such as Alzheimer’s disease and
Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for
which there are currently no approved treatment options.
ZUNVEYL is a patented drug approved as a new generation
acetylcholinesterase inhibitor (AChEI) for the treatment of
Alzheimer’s disease, with expected minimal gastrointestinal side
effects. ZUNVEYL’s active metabolite is differentiated from
donepezil and rivastigmine in that it improves the function of
neuronal nicotinic receptors, most notably the alpha-7 subtype,
which is known to have a positive effect on cognition.
Benzgalantamine is also being developed in combination with
memantine to treat moderate to severe Alzheimer’s dementia, and as
an intranasal formulation for Cognitive Impairment with mTBI.
Forward-looking Statements
This news release includes forward-looking statements within the
meaning of applicable securities laws. Except for statements of
historical fact, any information contained in this news release may
be a forward‐looking statement that reflects the Company’s current
views about future events and are subject to known and unknown
risks, uncertainties, assumptions and other factors that may cause
the actual results, levels of activity, performance or achievements
to be materially different from the information expressed or
implied by these forward-looking statements. In some cases, you can
identify forward‐looking statements by the words “may,” “might,”
“will,” “could,” “would,” “should,” “expect,” “intend,” “plan,”
“objective,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “target,” “seek,” “contemplate,” “continue”
and “ongoing,” or the negative of these terms, or other comparable
terminology intended to identify statements about the future.
Forward‐looking statements may include statements regarding the
potential closing of the Offering, the use of proceeds of the
Offering, receipt of regulatory and stock exchange approvals in
connection with Offering and completion of the Nasdaq uplisting.
Although the Company believes to have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. The Company cannot assure that the actual results will be
consistent with these forward-looking statements. These
forward‐looking statements speak only as of the date of this news
release and the Company undertakes no obligation to revise or
update any forward‐looking statements for any reason, even if new
information becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241112017064/en/
For further information: Michael McFadden, CEO Tel:
1-858-344-4375 info@alphacognition.com
Titan Partners Contact: Tel: (929) 833-1246
info@titanpartnersgrp.com
Alpha Cognition (NASDAQ:ACOG)
過去 株価チャート
から 10 2024 まで 11 2024
Alpha Cognition (NASDAQ:ACOG)
過去 株価チャート
から 11 2023 まで 11 2024
